Avidity Biosciences, Inc.

RNAMSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1599901

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$9.6M	$9.2M	$9.3M	$6.8M	$2.3M
Research and Development Expense	$191.0M	$150.4M	$101.2M	$37.6M	$14.5M
Operating Expenses	$245.2M	$188.1M	$127.4M	$51.1M	$19.7M
Operating Income (Loss)	-$235.6M	-$178.9M	-$118.1M	-$44.3M	-$17.3M
Interest Expense	—	—	—	$209.0K	$7.4M
Nonoperating Income (Expense)	$23.4M	$4.9M	$42.0K	-$78.0K	-$7.4M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$212.2M	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.6B	$628.6M	$638.8M	$427.6M	$333.9M
Assets, Current	$1.5B	$611.3M	$622.9M	$411.1M	$331.7M
Cash and Cash Equivalents, at Carrying Value	$219.9M	$185.1M	$340.4M	$320.4M	$321.5M
Accounts Receivable, after Allowance for Credit Loss, Current	—	$1.1M	$2.4M	—	—
Liabilities	$138.9M	$127.8M	$60.7M	$46.1M	$27.7M
Liabilities, Current	$98.0M	$80.7M	$51.9M	$29.7M	$14.6M
Long-term Debt	—	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$119.1M	-$136.3M	-$94.8M	-$37.1M	$2.5M
Net Cash Provided by (Used in) Investing Activities	-$130.1M	-$190.0M	-$82.5M	-$7.8M	-$235.0K
Net Cash Provided by (Used in) Financing Activities	$93.9M	$346.2M	$176.3M	$272.0M	$89.2M
Payments to Acquire Property, Plant, and Equipment	$4.2M	$2.8M	$3.7M	$1.1M	$235.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)